Tirilizumab can be used to treat advanced liver cancer and needs to be used as directed by a doctor The PD-1 receptor expressed by T cells binds to its ligands PD-L1 and PD-2, which can inhibit T cell proliferation and cytokine production. PD-1 ligands are upregulated in some tumor cells, and signaling through this pathway inhibits immune surveillance of tumor cells by activated T cells. Tirilizumab is a humanized recombinant anti-PD-1 monoclonal antibody for use in immunotherapy. It is indicated for the treatment of hepatocellular carcinoma (HCC) after at least one systemic therapy. A study evaluating the efficacy and safety of this product as monotherapy in the treatment of unresectable HCC with at least one prior systemic therapy showed an objective remission rate of 13.3%, a median progression-free survival of 2.7 months, and a median survival of 13.2 months. It is recommended to go to a regular hospital to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and choose the appropriate treatment program to avoid delaying the condition. Please strictly follow the doctor’s instructions for medication, do not self-medicate.